Related Experiment Video
Updated: Jan 9, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
Enhancing Adverse Event Identification and Management in Early-Phase Oncology Clinical Trials: The Emerging Role of
1From The University of Texas MD Anderson Cancer Center, Houston, Texas.
Background:
Adverse events (AEs) are unintended, harmful effects that occur in clinical trials, particularly in early-phase oncology clinical trials (EPOCT), where the risk of adverse effects from experimental therapies is high. Effective AE identification and management are essential for ensuring patient safety, improving outcomes, and advancing research. Advanced practice providers (APPs) play a key role in detecting and managing AEs, serving as a bridge between clinical care and research. However, their full impact on EPOCT remains underexplored.
Purpose:
This integrative review examines existing literature on AE identification, reporting, and management in EPOCT. It explores the role of APPs in managing AEs, emphasizing their impact on patient outcomes, clinical trial efficiency, and oncology science.
Methods:
A systematic search of peer-reviewed literature from 2020 to 2025 was conducted using various databases. Inclusion criteria were studies addressing AE management in EPOCT, patient-reported outcomes (PROs), and APP roles. Studies unrelated to oncology, AE management, or health-care providers were excluded.
Results:
Findings highlight the variability in AE reporting and the growing utility of electronic PRO tools in capturing timely and accurate data. Advanced practice providers contribute significantly to outpatient AE management, reducing emergency visits and improving treatment adherence. However, challenges remain, including underreporting with clinician-based tools, lack of standardized APP training, and limited comparison to physician-led AE management.
Conclusion:
APPs serve as key players in enhancing AE reporting and improving clinical trial processes. Future research should focus on standardizing structured training programs for APPs and comparative studies assessing the effectiveness of APP-led care.
Insights
Advanced practice providers (APPs) are crucial for managing adverse events (AEs) in early-phase oncology clinical trials (EPOCT). Their involvement improves AE reporting and patient outcomes, though standardized training and comparative studies are needed.
Area of Science:
- Oncology
- Clinical Trials
- Patient Safety
Background:
- Adverse events (AEs) pose significant risks in early-phase oncology clinical trials (EPOCT) due to experimental therapies.
- Effective AE identification and management are vital for patient safety, trial success, and scientific advancement.
- Advanced practice providers (APPs) are integral to AE detection and management, bridging clinical care and research, yet their full impact in EPOCT is not fully understood.
Purpose of the Study:
- To review the literature on AE identification, reporting, and management within EPOCT.
- To explore the specific role and impact of APPs in managing AEs during EPOCT.
- To emphasize the influence of APPs on patient outcomes, clinical trial efficiency, and oncology research.
Main Methods:
- Systematic literature search conducted from 2020 to 2025 across multiple databases.
- Inclusion criteria focused on studies related to AE management in EPOCT, patient-reported outcomes (PROs), and APP roles.
- Exclusion criteria targeted studies not relevant to oncology, AE management, or healthcare providers.
Main Results:
- AE reporting shows variability; electronic PRO tools enhance data capture timeliness and accuracy.
- APPs significantly contribute to outpatient AE management, reducing emergency visits and improving treatment adherence.
- Challenges include underreporting with clinician tools, inconsistent APP training, and limited data comparing APP-led to physician-led AE management.
Conclusions:
- APPs are essential for improving AE reporting and optimizing clinical trial processes.
- Future research should prioritize standardizing APP training programs.
- Comparative studies evaluating the efficacy of APP-led AE management are recommended.
More Related Videos
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Clinical Trials: Overview
Patient-centered Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...

